TickerFacts.

Company research / NNNN

Anbio Biotechnology (NNNN)

Build a valuation ↗↓ Download CSV

CIK 0001982708 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Anbio Biotechnology reported revenue of $8.65M. Revenue grew 5.6% from the prior annual period.

Key ratios (year ended 2025-12-31)

87.2%
Gross margin
66.7%
Operating margin
74.1%
Net margin
21.2%
Return on year-end equity
5.6%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 6-K (current report) · 2026-05-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2025-12-312024-12-312023-12-312022-12-31
Revenue$8.65M$8.19M$6.71M$23.54M
Cost of Revenue$1.10M$2.30M$3.35M$10.98M
Gross Profit$7.54M$5.89M$3.36M$12.56M
R&D Expense$201.3K$454.2K$134.7K$200.0K
Operating Income$5.77M$2.00M$1.96M$10.20M
Net Income$6.40M$2.37M$2.25M$10.01M
EPS (Diluted)$0.15$0.056$0.10$100112.00
Total Assets$30.24M$18.92M$15.81Mn/a
Total Liabilities$87.8K$1.73M$993.1Kn/a
Shareholders' Equity$30.16M$17.19M$14.82M$12.55M
Cash & Equivalents$7.77M$11.76M$9.69Mn/a
Operating Cash Flow-$6.74M$2.08M$898.4K$4.45M
Weighted Average Diluted Shares43.67M42.29M21.44Mn/a
EPS (Basic)$0.15$0.056$0.10$100112.00

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView